Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Apr 24;21(5):e25113.
doi: 10.5812/traumamon.25113. eCollection 2016 Nov.

Evaluation of the Effect of Glibenclamide in Patients With Diffuse Axonal Injury Due to Moderate to Severe Head Trauma

Peyman Zafardoost  1 , Amir Abbas Ghasemi  1 , Firooz Salehpour  1 , Chia Piroti  1 , Ehsan Ziaeii  1
Affiliations

Evaluation of the Effect of Glibenclamide in Patients With Diffuse Axonal Injury Due to Moderate to Severe Head Trauma

Peyman Zafardoost et al. Trauma Mon. .

Abstract

Background: Traumatic brain injury (TBI) is a major health problem worldwide. Secondary injuries after TBI, including diffuse axonal injury (DAI) often occur, and proper treatments are needed in this regard. It has been shown that glibenclamide could reduce secondary brain damage after experimental TBI and improve outcomes.

Objectives: We aim to evaluate the role of glibenclamide on the short-term outcome of patients with DAI due to moderate to severe TBI.

Patients and methods: In this controlled randomized clinical trial, 40 patients with moderate to severe TBI were assigned to glibenclamide (n = 20) and control (n = 20) groups. Six hours after admission the intervention group received 1.25 mg glibenclamide every 12 hours. The Glasgow coma scale (GCS) was administered at admission, in the first 24 and 48 hours, at one week post-trauma and at discharge. The Glasgow outcome scale (GOS) was also administered at discharge. All results were evaluated and compared between groups.

Results: Patients treated with glibenclamide compared to the control group had a significantly better GCS score one week post-trauma (P = 0.003) and at discharge (P = 0.004), as well as a better GOS score at discharge (P = 0.001). The glibenclamide group also had a shorter length of hospital stay compared to the control group (P = 0.03). In the control group, two patients (10%) died during the first week post-trauma, but there was no mortality in the glibenclamide group (P = 0.48).

Conclusions: Treatment with glibenclamide in patients with DAI due to moderate to severe TBI significantly improves short-term outcomes.

Keywords: Diffuse Axonal Injury; Glibenclamide; Outcome; Traumatic Brain Injury.

PubMed Disclaimer

References

    1. Ingebrigtsen T, Mortensen K, Romner B. The epidemiology of hospital-referred head injury in northern Norway. Neuroepidemiology. 1998;17(3):139–46. - PubMed
    1. Masson F, Thicoipe M, Aye P, Mokni T, Senjean P, Schmitt V, et al. Epidemiology of severe brain injuries: a prospective population-based study. J Trauma. 2001;51(3):481–9. - PubMed
    1. Robles JF, Navarro JEV, Maglinao MLD, Matawaran BJ, Andag-Silva AA, Mercado-Asis LB. Traumatic Injury to the Brain and Endocrine Evaluation of the Anterior Pituitary a Year After the Event (The TRIBE Study). Int J Endocrinol Metab. 2009;2009(2):72–81.
    1. Syed Hassan ST, Jamaludin H, Abd Raman R, Mohd Riji H, Wan Fei K. Mental Trauma Experienced by Caregivers of patients with Diffuse Axonal Injury or Severe Traumatic Brain Injury. Trauma Mon. 2013;18(2):56–61. doi: 10.5812/traumamon.11522. - DOI - PMC - PubMed
    1. Hattori N, Huang SC, Wu HM, Liao W, Glenn TC, Vespa PM, et al. Acute changes in regional cerebral (18)F-FDG kinetics in patients with traumatic brain injury. J Nucl Med. 2004;45(5):775–83. - PubMed